<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289650</url>
  </required_header>
  <id_info>
    <org_study_id>STU00205327</org_study_id>
    <nct_id>NCT03289650</nct_id>
  </id_info>
  <brief_title>Extended Release Tacrolimus vs. Twice-Daily Tacrolimus</brief_title>
  <official_title>Once-Daily Extended-Release Tacrolimus vs. Twice-Daily Tacrolimus: Impact on T-Cell Subpopulations and Markers of Renal Tubule-toxicity in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lorenzo Gallon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the study is to prospectively investigate the impact of two maintenance&#xD;
      calcineurin inhibitor immunosuppressive regimens: once-daily extended release tacrolimus and&#xD;
      twice-daily tacrolimus on subpopulations of T and B cells and alloreactive T cells as well as&#xD;
      on renal allograft function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney transplantation is the treatment of choice for most patients with end-stage renal&#xD;
      disease. Lifelong immunosuppressive therapies are required to prevent organ rejection.&#xD;
      However, long term exposure to immunosuppressive therapy after kidney transplantation can&#xD;
      place patients at risk for multiple adverse events. The optimal immunosuppressive therapy is&#xD;
      not well established. Tacrolimus, a calcineurin inhibitor (CNI) is highly effective in&#xD;
      preventing acute rejection after organ transplantation (2). It is used as part of the&#xD;
      immunosuppression regimen for the majority of kidney and liver transplant recipients (3).&#xD;
      However, treatment with current formulation of Tacrolimus generates high peaks and low&#xD;
      troughs in drug concentrations in the blood. It is known that high exposure to CNI is&#xD;
      associated with renal toxicities and adverse events (4). New once-daily dosage formulations&#xD;
      are now developed with the hope of minimizing side effects while maintaining excellent&#xD;
      outcomes (5-8).&#xD;
&#xD;
      LCP-Tacro (Envarsus® XR, Veloxis Pharmaceuticals), a new once-daily formulation of&#xD;
      tacrolimus, was approved by the FDA in 2015 for conversion from twice-daily tacrolimus in&#xD;
      kidney transplant recipients. It is a prolonged-release tacrolimus formulation, utilizing a&#xD;
      MeltDose drug delivery technology designed to improve the bioavailability of drugs with low&#xD;
      water solubility (1). Recent clinical data demonstrated that once-daily LCP-Tacro has&#xD;
      improved pharmacokinetic bioavailability, rapid achievement of therapeutic trough levels,&#xD;
      less fluctuation and swing in whole blood concentration, non-inferior efficacy and similar&#xD;
      safety, with lower tacrolimus dose than other tacrolimus formulations.&#xD;
&#xD;
      The target population is adult recipients of immediately functioning living and deceased&#xD;
      donor renal allografts. Immediate function will be defined as the absence of the need for&#xD;
      hemodialysis in the first week following renal transplantation.&#xD;
&#xD;
      Prospective randomized single center open label study of 2 groups of kidney transplant&#xD;
      patients&#xD;
&#xD;
        -  Group 1 : standard of care (SOC) control group will receive tacrolimus twice-daily&#xD;
           (n=25)&#xD;
&#xD;
        -  Group 2 : LCP-Tacro (Envarsus® XR) group will receive LCPT tablets once daily (n=25)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in kidney transplant function from 2 weeks post transplant through 12 months post transplant</measure>
    <time_frame>Measured at 2 weeks post transplant, 3 months post transplant, 12 months post transplant</time_frame>
    <description>Kidney transplant function assessed with kidney injury markers using Myriad-RBM KidneyMAP panel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in subpopulations of T cells from 2 weeks post transplant through 12 months post transplant</measure>
    <time_frame>Measured at 2 weeks post transplant, 3 months post transplant, 12 months post transplant</time_frame>
    <description>Blood, urine and kidney tissue analysis via serial flow cytometric immunophenotyping (includes regulatory T and B cell populations as well as immune functions).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to incidence of acute rejection</measure>
    <time_frame>Measured at 3 months post transplant, 12 months post transplant</time_frame>
    <description>Acute rejection of kidney transplant is determined via biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to incidence of graft loss</measure>
    <time_frame>Measured at 3 months post transplant, 12 months post transplant</time_frame>
    <description>Graft loss is determined via biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to incidence of subject death</measure>
    <time_frame>Through 12 months post transplant</time_frame>
    <description>Subject survival status is continually monitored via routine follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in allograft immunohistopathology profile</measure>
    <time_frame>Measured at 3 months post transplant, 12 months post transplant</time_frame>
    <description>Tissue analysis via immunohistopathological staining and microscopic examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Rejection of Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Standard of care tacrolimus twice-daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended-release tacrolimus once-daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>immunosuppressive agent tacrolimus, given twice-daily</description>
    <arm_group_label>Standard of care tacrolimus twice-daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Extended Release Oral Tablet [Envarsus]</intervention_name>
    <description>immunosuppressive agent extended-release tacrolimus, given once daily</description>
    <arm_group_label>Extended-release tacrolimus once-daily</arm_group_label>
    <other_name>LCP-tacro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients who are males or females aged 18-65 years. 2. Use of the following induction&#xD;
        medications: basiliximab and rituximab. 2. Donors aged 18-65 years. 3. No prior organ&#xD;
        transplant 4. Patients who are single-organ recipients (kidney only). 5. Women who are of&#xD;
        childbearing potential must have a negative serum pregnancy test before transplantation and&#xD;
        agree to use a medically acceptable method of contraception throughout the treatment&#xD;
        period.&#xD;
&#xD;
        6. Subject (recipient) is able to understand the consent form and give written informed&#xD;
        consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Delayed graft function (please see above).&#xD;
&#xD;
          2. Known sensitivity or contraindication to alemtuzumab, Envarsus® XR, tacrolimus or MMF.&#xD;
&#xD;
          3. Use of the following induction medications: basiliximab and rituximab&#xD;
&#xD;
          4. Patient with significant or active infection.&#xD;
&#xD;
          5. Patients with a positive flow cytometric crossmatch using donor lymphocytes and&#xD;
             recipient serum.&#xD;
&#xD;
          6. Patients with PRA &gt; 40%&#xD;
&#xD;
          7. Patients with current or historic donor specific antibodies&#xD;
&#xD;
          8. Body Mass Index (BMI) of &lt; 18 or &gt; 35&#xD;
&#xD;
          9. Patients who are pregnant or nursing mothers.&#xD;
&#xD;
         10. Patients whose life expectancy is severely limited by diseases other than renal&#xD;
             disease.&#xD;
&#xD;
         11. Ongoing active substance abuse, drug or alcohol.&#xD;
&#xD;
         12. Major ongoing psychiatric illness or recent history of noncompliance.&#xD;
&#xD;
         13. Significant cardiovascular disease (e.g.):&#xD;
&#xD;
               -  Significant non-correctable coronary artery disease;&#xD;
&#xD;
               -  Ejection fraction below 30%;&#xD;
&#xD;
               -  History of recent myocardial infarction.&#xD;
&#xD;
         14. Malignancy within 3 years, excluding non-melanoma skin cancers.&#xD;
&#xD;
         15. Serologic evidence of infection with HIV or HBVs-Ag positive.&#xD;
&#xD;
         16. Patients with a screening/baseline total white blood cell count &lt; 4,000/mm3; platelet&#xD;
             count &lt; 100,000/mm3; triglyceride &gt; 400 mg/dl; total cholesterol &gt; 300 mg/dl.&#xD;
&#xD;
         17. Investigational drug within 30 days prior to transplant surgery.&#xD;
&#xD;
         18. Anti-T cell therapy within 30 days prior to transplant surgery.&#xD;
&#xD;
         19. Diagnosis of atypical-Hemolytic Uremic Syndrome (aHUS).&#xD;
&#xD;
         20. Subjects transplanted with a Hepatitis C NAT-positive kidney.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Lorenzo Gallon</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

